Nature's Sunshine Reports Strong Q1 Results, Reaffirms Guidance, and Approves New Stock Incentive Plan
NATR has more than doubled off its 52-week low of $12.9.
Summary
Nature's Sunshine Products reported strong Q1 2026 financial results, including a 9% increase in net sales and a 16% rise in GAAP EPS, and reaffirmed its full-year guidance, alongside shareholder approval of a new stock incentive plan.
Key Events · Earnings and Guidance · NATR
-
Strong First Quarter Financial Results
Net sales increased 9% to $122.9 million, GAAP EPS rose 16% to $0.29, and Adjusted EBITDA grew 33% to $14.6 million for the quarter ended March 31, 2026.
-
Full-Year Guidance Reaffirmed
The company maintained its 2026 net sales outlook, expecting a range of $500 - $515 million, and reaffirmed adjusted EBITDA guidance of $50 - $54 million.
-
Shareholders Approve New Stock Incentive Plan
Shareholders approved the 2026 Stock Incentive Plan, authorizing up to 1,500,000 shares of common stock for issuance, representing approximately 8.36% potential dilution based on current outstanding shares.
-
Solid Financial Position
Nature's Sunshine reported $87.6 million in cash and cash equivalents with zero debt as of March 31, 2026.
Analysis · NATR · Life Sciences
The company delivered robust first-quarter financial performance with significant growth in sales, GAAP EPS, and Adjusted EBITDA, while reaffirming its full-year outlook. This indicates strong operational momentum and financial health. Concurrently, shareholders approved a new stock incentive plan, which, while a standard governance item, authorizes a notable amount of potential share dilution for employee compensation.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NATR was trading at $27.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $429.8M. The 52-week trading range was $12.90 to $28.14. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.